The gut microbiota has a well-established role in the regulation of host homeostasis. Multiple factors control the composition and function of the microbiota. The westernization of diet, a shift away from nutrient-dense foods toward diets high in saturated fats, has been implicated in the rise of chronic inflammatory diseases such as inflammatory bowel disease (IBD). Diet is critical in the development and maintenance of a healthy microbiome, where dietary fiber (found in the highest amounts in fruits, vegetables, and legumes) is metabolized by the microbiome. In turn, the bacterial metabolites of dietary fiber, short chain fatty acids (SCFAs), regulate gut homeostasis. SCFAs engage G-protein coupled receptors (GPRs) and act as histone deacetylase inhibitors (HDACi) to module epithelial and immune cell functions in the intestines, where they generally promote an anti-inflammatory state. This review highlights the functions of SCFAs and their roles in the pathogenesis of IBD to provide insights into their potential therapeutic application for the treatment of IBD for the purposes of precision medicine.
Introduction
Ulcerative colitis (UC) and Crohn's disease (CD), collectively known as inflammatory bowel disease (IBD), have emerged as a significant health challenge in the twentyfirst century. IBD affects millions of people in the United States, Europe, and Asia, with increasing incidence and prevalence worldwide. 1 The role of microbiota in the pathogenesis of IBD is well established; however, the components of the microbiota that are responsible for these effects remain largely unknown. Studies have identified a crucial role for gut microbiota metabolites in modulating intestinal homeostasis and immunity, with dietary fibers and their bacterial fermentation products, short chain fatty acids (SCFAs), playing an essential part. 2, 3 Of particular interest are the SCFAs acetate, propionate, and butyrate, which collectively account for > 95% of the SCFA population. 4 Their importance to intestinal health cannot be overstated, as SCFAs have been linked to protection against IBD, allergic asthma, and diabetes. [5] [6] [7] [8] In this review, we will highlight the role of SCFAs in barrier protection and in the pathogenesis of IBD.
Formation of SCFAs
The intestines harbor trillions of bacteria that have developed both a mutualistic and symbiotic relationship with their host. The intestinal microbiome plays pertinent roles in maintaining homeostasis, and alterations in the microbiome are associated with chronic inflammatory conditions including IBD, diabetes, obesity, and allergic asthma. 6, 8, 9 Among various microbiota metabolites important in regulation of host physiology and health, SCFAs (including acetate, propionate, and butyrate) are derived from the bacterial fermentation of dietary fibers, such as inulin, which escape absorption in the small intestines and enter into the colon 4 ( Fig. 1) .
Acetate is the most abundantly produced SCFA, followed by propionate and butyrate in a 3:1:1 molar ratio, respectively. 9 SCFA formation is dictated by both the type of bacteria and type of dietary fiber present in the colon. For example, most bacteria produce acetate which can be derived from acetyl-CoA or alternatively via formate, hydrogen, and carbon dioxide, via the Wood-Ljungdahl pathway. 10 Although many bacteria can produce acetate, propionate production occurs most commonly via the succinate pathway, which requires hexoses and pentoses found in the dominant phylum of Bacteroidetes. 10, 11 Propionate can also be produced by species such as Veilonella using lactate through the acrylate pathway or through the propanediol pathway found in Roseburia and Ruminococcususes, which use fucose and rhamnose. 10, 11 Conversely, butyrate is primarily produced through condensation of a thiol group of coenzyme A with the carboxy group of acetyl-CoA, resulting in butyryl-CoA, which can then ultimately be converted to butyrate. 10, 12 There are many butyrate producing species, with the phylum Firmicutes being the primary producer in the human colon. 13 
Transport of SCFAs
SCFAs, particularly butyrate, provide colonic cells with 80% of their daily energy supply and thus appreciable quantities are not found in the portal vein. 14 This is in contrast to acetate and propionate, which are primarily taken up by colonocytes and transported into the portal vein for metabolism in peripheral tissues such as muscle. 4 SCFA absorption occurs by three mechanisms: passive diffusion, electroneutral, or electrogenic uptake 15 ( Fig. 1) . The charge of a SCFA determines whether its uptake occurs via passive diffusion or a carrier mechanism. For example, passive diffusion of SCFAs is primarily seen when SCFAs are in the protonated form; this is a major mechanism of SCFA transport at physiological pH. 16 In contrast, SCFAs in anion form are dependent on carrier-mediated uptake, which can occur through four primary transporters. Monocarboxylate transporter 1 (MCT1) and MCT4 are electroneutral transporters, which rely on hydrogen 16 in contrast to sodium coupled monocarboxylate transport 1 (SMCT1) and SMCT2, which rely on sodium and are electrogenic and electroneutral transporters, respectively. 16 
SCFA mechanisms of action
The effects of SCFAs in the intestines and elsewhere are derived from their ability to stimulate three G-protein coupled receptors (GPRs), GPR41, GPR43, and GPR109a, as well as their ability to act as histone deacetylase inhibitors (HDACi) (Fig. 1) . GPR41 is coupled to the pertussis toxin-sensitive G i/o family, which regulates cyclic antimicrobial peptide (cAMP) production. GPR41 has its highest affinity for propionate > butyrate > >acetate.
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GPR41 is expressed in many cells and tissues, but is found in appreciable levels in peripheral blood monocytes (PBMC), dendritic cells (DC), and polymorphonuclear neutrophils (PMN), as well as in the spleen, lymph nodes, bone marrow, lung, small intestine, and adipose tissue. 17 Conversely, GPR43 expression is more restricted, as it is located mainly in the intestines and specific immune populations such as PMN, PBMC, Figure 1 . Formation, transport, and mechanisms of action of short chain fatty acids (SCFAs 4, and 12 expression while also increasing lactobacillus adherence and decreasing Escherichia coli adherence in vitro. Thus, the role of SCFAs in modulating mucin synthesis serves as an important mechanism by which the host can allow for the colonization of beneficial bacteria, which may outcompete pathogenic bacteria and prevent inflammation and infection. Thus, a deeper understanding of the role of mucin could lead to development of probiotics that would allow for alteration of the microbiome through colonization and expansion while also protecting from gastrointestinal infection and inflammation, which could be potentially used in precision medicine to prevent and treat gastrointestinal infection and inflammation.
SCFA regulation of antimicrobial peptides
In addition to promoting mucus production, SCFAs stimulate antimicrobial peptides (AMPs), which are critical for innate defenses against pathogens and serve as a first line of defense for the underlying epithelial layer. In this regard, Hase et al. 33 demonstrated that the human cathelicidin LL-37 was expressed constitutively in the colon, specifically in cells at the surface and in the upper crypts. This effect was independent of the commensal bacteria, as human fetal colon transplanted onto the backs of severe combined immunodeficiency (SCID) mice under sterile conditions demonstrated similar LL-37 expression as human colon in vivo. Additionally, butyrate increased levels of LL-37 in Caco-2 and HT-29 cells. The mechanism underlying the stimulation of LL-37 by butyrate was uncovered by Schauber et al., 34 who showed that LL-37 expression was dependent on butyrate activation of MEK in the human colon cancer cell line SW620. The potential implications of LL-37 in host protection were unraveled by Raqib et al., 35 who demonstrated that butyrate upregulated the expression of CAP-18, the rabbit homologue to LL-37, and that this upregulation was critical for protection against shigella infection, as pretreatment of rabbits with butyrate prior to shigella infection led to decreased severity of infection. This is an important finding because it suggests that prevention and treatment of gastrointestinal bacterial infections could be done through dietary intervention. However, the contribution of AMPs in the protection against specific pathogens like shigella must be further examined as SCFAs stimulate mucus production, and dietary deficiencies in fiber have been shown to increase mucus-degrading bacteria and susceptibility to pathogens. 36 Aside from cathelicidin, Zeng et al. 37 found that in IPEC-J2 cells (a porcine-derived colon cell line) acetate, propionate, butyrate, as well as phenyl derivatives of butyrate, increased β-defensin 2 and β-defensin 3 expression. This finding was further elucidated by Xiong et al., 38 who found that butyrate could stimulate the in vivo expression of β-defensin 2 and β-defensin 3 in the colon and ileum of pigs, which ultimately led to protection against severe infection when pigs were challenged with E. coli. This effect was found to be through HDACi, as treatment of 3D4/2 cells (immortalized porcine alveolar macrophages) led to increased expression of several AMPS including β-defensin 2 and β-defensin 3. Thus, this finding suggests an important role of macrophages in AMP production in response to SCFAs, while also confirming the work of Raqib et al., 35 demonstrating the potential feasibility of diet modification in the protection of gastrointestinal infection in precision medicine. Lastly, our group recently uncovered that SCFAs via GPR43 regulated the expression of REGIIIγ and β-defensin 1, 3, and 4. 39 This was dependent on SCFA induction of STAT3 and mTOR activation, as both inhibition of STAT3 and mTOR chemically or with siRNA knockdown abrogated the effects of SCFAs on AMP production. 42 who showed that butyrate inhibited proliferation in cryptless animals and around areas of ulceration where the stem cell compartment would be exposed to the high luminal butyrate concentration. Thus, this study suggests that crypts, as well as colonocytes, are critical in metabolizing butyrate and creating a butyrate gradient, which permits HAT activity at the base of the crypt. Additionally, the findings of both these articles support the long-term health effects of a high fiber diet in protecting against the development of colorectal cancer. 43 
SCFAs regulation of the epithelial layer

SCFA regulation of tight junctions
SCFAs and immune regulation
The immune cells that reside intraepithelially and in the lamina propria of the intestines play a vital role in regulation of host homeostasis to microbiota, with accumulating evidence suggesting that SCFAs are the key regulator of this process (Fig. 2) .
SCFA regulation of neutrophils
SCFAs have been shown to regulate neutrophil functions. In this regard, Vinolo et al. 55 demonstrated the differential effects of SCFAs on neutrophil killing. This was examined via the isolation of rat peritoneal neutrophils, in which butyrate inhibited the phagocytosis and killing of C. albicans, while also decreasing reactive oxygen species (ROS) production in neutrophils. This is in contrast to propionate, which had no effect on phagocytosis, killing, or ROS production; similarly, acetate only moderately increased ROS production. Vinolo et al. 56 later uncovered that butyrate and propionate treatment of neutrophils diminished TNFα, cytokine-induced neutrophil chemoattractant-2 (CINC-2αβ), and nitric oxide (NO) production in LPS-treated neutrophils. This downregulation of inflammatory cytokines was found to be HDACidependent and cyclooxygenase (COX) independent. These data by Vinolo et al. point toward a major role of HDACi in modulating neutrophil function, given the potency of butyrate compared to other SCFAs. More interestingly, it implicates butyrate as a key player in priming neutrophils in the gut, possibly to protect against invading pathogens. With these data, it would be of great interest to further examine the role of systemic butyrate, possibly through the use of tributyrin, the rapidly absorbed prodrug form of butyric acid. 57 SCFA modulation of chemotaxis was uncovered by Sina et al., 58 who examined chemotaxis of neutrophils under acute and chronic inflammation in wild-type (WT) and GPR43 KO mice. In the study, it was shown that GPR43 KO mice had decreased neutrophil influx into the colon upon both acute and chronic inflammation. Using transwell assays, they found that SCFAs activate neutrophil migration, and that this migration was abrogated with GPR43 KO. However, under noninflammatory conditions, GPR43 KO neutrophils in vivo did not demonstrate any alterations in chemotaxis. Most interesting though, is that GPR43 KO aggravated acute DSS colitis, but was protective in chronic colitis. This begs the question as to the differential regulation of GPR43 and its importance under non-inflammatory versus inflammatory conditions, and in acute versus chronic inflammation. Given that neutrophilic infiltrate is a hallmark of ulcerative colitis, it would be of interest to investigate whether a GPR43 antagonist is beneficial in modulating chronic colitis and colitis-associated cancer for the purpose of precision medicine. 64 demonstrated that SCFAs as compared to longchain fatty acids, were protective in the preventative setting, but not the treatment setting, in experimental EAE. This mechanism occurred via SCFA induction of Tregs, which was demonstrated by adoptive transfer of Tregs from propionate-treated or non-treated mice into recipient mice with simultaneous induction of EAE. Additionally, Schwarz et al. showed that butyrate induction of Tregs was protective against contact hypersensitivity reactions in the skin, similar to their role in colitis and EAE. 65 These data support that SCFAs may be an important environmental factor that could dictate the onset of inflammatory diseases; however, the ability of SCFAs to modulate inflammation after disease onset is less convincing. The lack of SCFA protection postinflammation onset may result from their differential effects on other T cell populations as well as their concentration. For example, Sałkowska et al. 66 found in human Jurkat T cells that butyrate decreased RORγt expression in naïve CD4 T cells under Th17 polarizing conditions, but promoted RORγt and IL-17A expression if butyrate was added to differentiated Th17 cells. Furthermore, Park et al. 67 found that administration of super physiological doses of SCFAs led to the development of T cell-mediated ureteritis, which progressed to kidney hydronephrosis. These data offer interesting perspectives on the role of SCFAs on inflammation as they demonstrate that SCFAs may not be a beneficial treatment for acute inflammation, and that dosing of SCFAs could be critical in determining their therapeutic potential. Additionally, Asarat et al. 68 found that PBMCs co-cultured with T cells in the presence of LPS and SCFAs decreased Th17 differentiation, while increasing Treg differentiation and decreasing IL-6 production, with butyrate being the most potent inducer of Tregs. butyrate induced an antimicrobial signature characterized by the expression of S100A8, S100A9, S10012, LYZ, and FCN1, which was driven by inhibition of HDAC3. Thus, these data implicate SCFAs as major modulators of basal levels of inflammation driven by macrophages, and also exemplify their potentially protective effect against pathogens through the promotion of antimicrobial responses at epithelial surfaces. 74 demonstrated that in a treatment model where butyrate supplementation began the day prior to DSS colitis onset rather than 5-7 days prior, butyrate was no better than control in terms of colitis severity in the acute DSS colitis model. 74 The reason for SCFAs' effect in prevention rather than treatment of colitis may be offered by the findings from Kaiko et al., 42 who found that butyrate inhibition of stem cell expansion led to increased ulcer size in the acute model of DSS colitis. Thus, the beneficial effects of butyrate on inflammation may be partially counteracted by this delay in repair to ulcerated tissue. To circumvent this issue, in future it may be beneficial to begin investigating compounds that target individual GPRs or HDACs in IBD.
SCFA regulation of dendritic cells
Concluding remarks
Given the importance of SCFAs in barrier protection and regulation of inflammation, dietary supplementation of SCFAs or modulation of diet to increase dietary fiber intake is an attractive option for potentially reversing the increase we see today in chronic inflammatory diseases. This could be beneficial in the preventative setting, where SCFAs have been linked to lower risk of chronic inflammatory diseases and colorectal cancer. 8, 43, 86 However, although SCFAs have a clear role in the regulation of host immunity, it is unclear whether SCFAs represent a feasible treatment following the onset of chronic inflammatory conditions. This is further supported by the conflicting clinical data which, to date, have failed to show conclusive evidence for the use of SCFAs in the acute setting. Nevertheless, further work is needed in this area for the purposes of precision medicine if we hope to one day treat IBD patients with chemical agonists or antagonists of GPRs or HDACs.
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